Business
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. The SIO Amendment provides, among other things, for a revised...
About this update from Neural Therapeutics Inc.
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. The SIO Amendment provides, among other things, for a revised structure of the previously announced concurrent financing, and the Company also announces the rescheduling of its shareholder meeting and the grant of restricted share units.","length":725,"tagName":"p"},{"type":"text","content":"Amendment to Concurrent Financing","length":33,"tagName":"p"},{"type":"text","content":"Pursuant to the SIO Amendment, the parties have agreed to revise the structure of the previously announced concurrent financing in connection with the Series B Transactions.","length":173,"tagName":"p"},{"type":"text","content":"As previously disclosed, the concurrent financing was structured as an equity private placement of units of 1001257530 Ontario Inc. ("CWE Newco B"). Under the amended terms, the financing will instead be completed directly by CWE through a non-brokered private placement of unsecured convertible debentures ("CWE Debentures") for aggregate gross proceeds of up to $1,000,000 (the "Concurrent Financing"), or such other amount as determined by CWE.","length":477,"tagName":"p"},{"type":"text","content":"The CWE Debentures will bear interest at a rate of 9.0% per annum, calculated on a simple, non-compounding basis, payable quarterly in cash, and will mature 24 months from the date of issuance unless earlier converted or repaid. The principal amount of the CWE Debentures, together with any accrued and unpaid interest, will be convertible at the option of the holder into shares of the resulting issuer (the "Resulting Issuer") at a conversion price of $0.12 per share (on a post-consolidation basis). In connection with the completion of the Series B Transactions, the CWE Debentures will be exchanged on a one-for-one basis for equivalent debentures of the Resulting Issuer on substantially the same economic terms. The Result...